Worse Odor Identification is Associated with Poorer Cognitive Function in pre-MCI Individuals: A Meta-analysis

Jobin, Benoît [1,2,3], **Zigrand,** Coline [4,6], **Frasnelli**, Johannes [2,5,6], **Boller**, Benjamin [1,2] & **Albers**, Mark W [3,7]

[1] Department of Psychology, Université du Québec à Trois-Rivières, Qc, Canada.

[2] Research Centre of the Institut universitaire de gériatrie de Montréal, Qc, Canada.

[3] Department of Neurology, Massachusetts General Hospital, Boston, MA, United States.

[4] Department of Psychology, Université du Québec à Montréal, Qc, Canada.

[5] Department of Anatomy, Université du Québec à Trois-Rivières, Qc, Canada.

[6] Research Centre of the Hôpital du Sacré-Cœur de Montréal, Qc, Canada.

[7] Harvard Medical School, Boston, MA, United States.

Corresponding author: Benoît Jobin, benoit.jobin@uqtr.ca, +1 (514) 606-1530, 3351 Boulevard

des Forges, C.P. 500 Trois-Rivières (Québec) G9A 5H7, Local 3470 Léon-Provencher.

Abstract

Introduction: Odor identification correlates with Alzheimer's disease (AD) biomarkers, and its

decline may emerge before measurable cognitive deficits—as early as the subjective cognitive

decline (SCD) stage. We aimed to compare odor identification between SCD and cognitively

normal (CN) stages and investigate whether cognitive differences moderate olfactory deficits.

Methods: A systematic search of four databases identified studies assessing olfactory

identification and cognitive screening in individuals aged 50 years or older. A random-effects

meta-analysis was performed on 11 studies (660 SCD, 574 CN).

Results: Individuals with SCD exhibited lower olfactory identification scores compared to CN

participants (SMD = -0.67, 95%CI [-1.31, -0.03], p = .04). Meta-regression analyses indicated

that larger cognitive differences between groups were associated with more pronounced olfactory

deficits (β = -1.79, p = .02).

Discussion: Worse cognition in pre-MCI individuals is associated with impaired odor

identification, supporting the potential role of odor identification as a screen for AD biomarkers

and future cognitive decline.

Keywords: Subjective cognitive decline, Alzheimer's disease, Biomarker, Olfaction, Smell,

Olfactory identification, Meta-Analysis.

1. Background

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the

accumulation of amyloid-β plaques and tau neurofibrillary tangles, followed by widespread

neurodegeneration and cognitive decline, culminating in dementia.[1] Early identification of

individuals at risk for AD is critical for timely intervention, particularly as the disease progresses

over decades before the occurrence of first cognitive deficits,[2–4] and as therapies targeting

amyloid pathology and other early pathological stages become available.[5,6] Subjective cognitive

decline (SCD) refers to self-reported cognitive decline in the absence of measurable deficits on

neuropsychological tests.[7] SCD is considered the first symptom of AD, appearing at stage 2 of

the disease,[1,8] and has been associated with an increased risk for the development of mild

cognitive impairment (MCI) and progression to the dementia stages of the disease.[9,10]

While SCD is associated with an increased risk of cognitive decline, not all individuals

reporting SCD will decline.[10] Furthermore, the presence of AD biomarkers among individuals

with SCD varies considerably, ranging from 10% to 76%.[9,11,12] This broad variability suggests a

lack of diagnostic precision and highlights the heterogeneity of SCD as a clinical entity.

Therefore, SCD alone is not sufficient to predict cognitive decline, necessitating the

identification of additional reliable, and easily accessible markers that can improve the

specificity of early risk assessment.

One promising candidate for preclinical AD detection is odor identification impairment.

Multiple studies have demonstrated that odor identification is impaired at the dementia[13] and

MCI[14] stages and is thought to emerge even before measurable episodic memory deficits.[15,16]

The primary olfactory cortex morphometry is damaged in MCI[17–19] and olfactory identification is

associated with hippocampal volume and entorhinal cortex thickness in patients with MCI[20–26]

and individuals with SCD.[27] Olfactory identification is also associated with longitudinal tau

pathology accumulation within the central olfactory system in cognitively normal individuals.[28]

Several longitudinal studies have demonstrated that olfactory identification scores are associated

with cognitive decline in cognitively normal individuals[29–33] and conversion from MCI to

dementia stage.[34,35] Taken together, these findings suggest that olfactory impairment may

represent a subtle, early marker of neurodegeneration, and could have predictive value in the

detection of preclinical AD.

A prior meta-analysis[36] suggested a trend toward lower olfactory identification scores in

individuals with SCD compared to cognitively normal (CN) older adults. The number of

included studies was small (k = 5), limiting the analysis of potential moderators and the

interpretation of the conclusions. Since its publication, several new studies have examined

olfactory function in SCD. With the advent of treatments that mitigate the burden of amyloid

pathology at the MCI and early dementia stages, it is crucial to identify low-cost, non-invasive,

and accessible signs and markers for AD that manifest prior to the onset of measurable cognitive

deficits, particularly before the progression to MCI. Olfactory testing may thus offer a valuable

complement to existing cognitive screening tools and could aid in stratifying risk in clinically

normal individuals reporting cognitive concerns. The aim of the meta-analysis was (1) to

compare odor identification between older adults with SCD and CN older adults without

cognitive complaint, and (2) to evaluate the magnitude of olfactory identification impairment in

SCD by comparing the effect sizes of olfactory differences with those observed in general

cognitive screening measures (e.g., Montreal Cognitive Assessment - MoCA,[37] Mini-Mental

State Examination - MMSE[38]).

2. Methods

The protocol of this meta-analysis was not registered.

2.1 Study Eligibility Criteria

Eligible studies included a direct comparison of odor identification scores between

individuals with SCD and CN participants without cognitive impairment or cognitive complaint,

with both groups including men and women aged 50 years and older. The definition of SCD was

based on two core criteria: (1) self-reported cognitive decline relative to a previous performance

level and (2) normal cognitive performance on standardized cognitive tests, such as the MMSE

or the MoCA to exclude MCI. CN participants were required to be CN without objective

cognitive impairment (i.e., scoring > -1.5 standard deviations on cognitive tests) and without

self-reported complaints of cognitive decline. Studies were excluded if participants were younger

than 50 years of age, had a diagnosed cognitive impairment, or had a psychiatric or neurological

condition that could affect cognitive or olfactory function.

Outcome. Eligible studies had to assess olfactory identification using a validated

olfactory identification test to be included in the meta-analysis. The eligible tests included the

Sniffin' Sticks Identification Test (SSIT),[39] the Odor Perception Identification Test (OPID)[20]/ the

AROMHA Brain Health Test,[40] the University of Pennsylvania Smell Identification Test

(UPSIT),[41] or the Cross-Cultural Smell Identification Test (CC-SIT).[42] Similarly, eligible studies

were required to include a measure of general cognition functioning using a standard screening

test (MoCA or MMSE)[37,38] to allow for effect size comparisons across cognitive and olfactory

measures.

2.2 Search Strategy and Information Source.

A systematic literature search was conducted to identify relevant studies published up to

February 1st, 2025. The search was conducted in the PsycNET, PubMed, Academic Search

Complete (EBSCO), and Scopus databases. The following keywords and Boolean operators were

used: ("SCD" OR "subjective cognitive decline" OR "subjective cognitive impairment" OR

"subjective memory impairment" OR "subjective memory decline" OR "cognitive complaint*"

OR "memory complaint*" OR "cognitive concerns" OR "memory concerns") AND ("olfac*" OR

"smell" OR "olfactory dysfunction" OR "olfactory impairment"). Studies had to be published in

English.

After the removal of 106 duplicates, 113 titles and abstracts were screened for eligibility.

We excluded studies that were unrelated to the research question, review articles, case studies,

qualitative studies, or the absence of a control group. After the initial screening, 40 studies were

identified as potentially eligible and were further assessed for inclusion. After reviewing full-text

articles, 11 studies and 13 reports met the inclusion criteria (Figure 1).

Figure 1. PRISMA Flow Diagram of Study Selection.

The figure illustrates the study selection process based on PRISMA (Preferred Reporting

135   Items for Systematic Reviews and Meta-Analyses) guidelines.

2.3 Risk of Bias Assessment

The methodological quality of each included study was assessed using the Newcastle-

Ottawa Scale (NOS), as recommended.[43] The NOS[44] is a tool designed to evaluate the quality of

non-randomized case-control studies in meta-analyses, assessing three key domains: participant

selection, comparability between groups, and outcome ascertainment. The scoring system ranges

from 0 to 9 points, with higher scores indicating higher study quality. Studies scoring 0–3 were

considered at high risk of bias, 4–6 at moderate risk, and 7–9 at low risk. The risk of bias for

each study was independently evaluated by two reviewers (BJ and CZ). If disagreement

emerged, the most conservative score was assigned. No major disagreements occurred during

this process, and no studies were excluded based on quality assessment. The final risk of bias

scores for each included study are summarized in Supplementary Table 1.

2.4. Statistical Analyses

We conducted random-effects meta-analyses using the *meta* package in R. We

standardized mean differences (SMD, Hedges' *g*) for each study by comparing the mean scores

of SCD and CN groups. To improve variance estimation, we performed random-effects model

using the Hartung-Knapp adjustment, with effect sizes weighted by the inverse variance of their

standard errors. This approach provides robust confidence intervals and improves statistical

inference, especially in meta-analyses with small numbers of studies or high heterogeneity.[45–47]

We assessed heterogeneity using Cochran's Q statistic, Higgins' I^2 index, and τ^2 to quantify

between-study variability. High heterogeneity ($I^2 > 75\%$) prompted further investigation through

meta-regression. We conducted meta-regression analyses to examine the potential moderating

effects of *age*, *sex proportion* (female), *educational level* (years), and *test modality* on effect

sizes.

We assessed potential publication bias using visual inspection of funnel plots, Egger's

regression test, and the trim-and-fill method. Funnel plot asymmetry and Egger's test *p*-values <

.05 were considered indicative of potential bias. We used the trim-and-fill method to impute

missing studies and adjust the pooled effect size under the assumption of publication bias.

Statistical significance was set at *p* < .05 for all analyses.

3. Results

3.1 Study selection and characteristics

A total of 11 studies met the inclusion criteria, combining 660 individuals with SCD and 574 CN

participants (see Figure 1 & Table 1). Two reports/articles used the same sample, therefore this

dataset counted as a single study to avoid duplication.[48,49] According to the study quality

assessment, no studies were excluded for a high risk of bias (i.e., NOS scale ≤3) (Supplementary

Table 1).

Table 1. Characteristics of included studies.

Authors (Year)	n (SCD/CN)	Women % (SCD/CN)	SCD Age	CN Age	SCD Education	CN Education
Bouhaben et al. (2024)[50]	47/101	70%/61%	69.74 (6.83)	69.0 (7.98)	na (na)	na (na)
Chen et al. (2021)[18]	70/50	67%/64%	67.3 (5.7)	64.5 (4.4)	11.5 (3.3)	11.8 (2.9)
Dhilla Albers et al. (2016)[20]	74/70	23%/71%	77.0 (8.16)	75.0 (8.75)	16.0 (2.9)	17.0 (2.6)
Jobin et al. (2024)[51]	31/73	62% /63%	75.48 (9.22)	72.25 (9.13)	16.25 (2.5)	16.42 (3.62)
Papadatos et al. (2023)[27]	55/55	78%/81%	70.08 (7.0)	69.07 (5.56)	16.97 (3.1)	15.77 (3.24)
Risacher et al. (2017)[52]	10/10	60%/79%	72.2 (6.4)	68.5 (6.9)	17.5 (2.0)	17.6 (2.0)
Schmicker et al. (2023)[53]	17/18	47%/55%	71.7 (7.0)	73.5 (0.48)	13.8 (2.7)	14.3 (2.2)
Sohrabi et al. (2009)[54]	81/63	na / na	65.53 (7.3)	64.66 (7.73)	na (na)	na (na)
Tahmasebi et al. (2019)[48,49]	161/69	51%/63%	66.93 (10.32)	65.5 (10.4)	12.45 (3.55)	12.12 (4.01)
Wang et al. (2021)[55]	84/35	62%/49%	67.0 (5.6)	67.5 (5.3)	11.5 (3.3)	11.8 (2.9)
Weber et al. (2004)[56]	30/30	63%/43%	66.0 (8.9)	65.9 (9.7)	13.9 (3.5)	16.0 (3.0)
Authors (Year)	n (SCD/CN)	Olfactory/ Cognitive Test	SCD Olfactory Score	CN Olfactory Score	SCD Cognitive Score	CN Cognitive Score
Bouhaben et al. (2024)[50]	47/101	SSIT/MoCA	11.23 (3.74)	13.18 (1.61)	28.67 (1.12)	28.96 (1.10)
Chen et al. (2021)[18]	70/50	SSITMMSE	10.8 (2.3)	12.8 (2.0)	27.30 (2.00)	27.20 (1.80)
Dhilla Albers et al. (2016)[20]	74/70	OPID/MMSE	0.67 (0.17)	0.69 (0.17)	28.95 (1.38)	29.45 (0.84)
Jobin et al. (2024)[51]	31/73	OPID/MoCA	10.68 (2.95)	10.79 (2.74)	-0.24 (1.17)	0.29 (0.84)

Papadatos et al. (2023)[27]	55/55	BSIT/MoCA	10.33 (1.69)	10.6 (1.41)	27.22 (1.84)	27.93 (1.50)
Risacher et al. (2017)[52]	10/10	UPSIT/MoCA	35.7 (3.3)	34.5 (2.3)	26.10 (2.30)	26.80 (2.5)
Schmicker et al. (2023)[53]	17/18	SSIT/MMSE	9.41 (1.51)	9.06 (1.47)	28.10 (1.50)	29.10 (1.00)
Sohrabi et al. (2009)[54]	81/63	SSIT/MMSE	12.38 (2.18)	13.12 (1.49)	28.98 (1.06)	29.11 (1.07)
Tahmasebi et al. (2019)[48,49]	161/69	SSIT/MMSE	12.16 (2.57)	12.83 (2.16)	28.84 (1.22)	28.71 (1.00)
Wang et al. (2021)[55]	84/35	SSIT/MMSE	11.1 (2.2)	12.9 (2.0)	26.80 (2.00)	27.00 (1.50)
Weber et al. (2004)[56]	30/30	CC-SIT/MMSE	9.7 (1.7)	10.3 (1.3)	28.50 (1.5)	29.1 (1.00)

Note: CC-SIT: Cross-Cultural Smell Identification Test. MoCA: Montreal Cognitive

Assessment. MMSE: Mini-Mental State Examination. OPID: Odor Percept Identification. SSIT:

Sniffin' Sticks Identification Test. UPSIT: University of Pennsylvania Smell Identification Test.

Some studies did not report data on educational level or sex proportion (indicated as 'na').

Additionally, data from Tahmasebi et al. (2019) were provided by the authors and have been used

in multiple publications. MoCA score was available for only a subsample of participants (SCD n

= 18, CN n = 28 included in Jobin et al., 2024.

3.2 Main Effect (Olfactory Identification)

Meta-analysis of the pooled SMD revealed that SCD groups exhibited significantly lower

olfactory identification scores compared to CN groups (SMD= -0.67, 95% CI [-1.31, -0.03], *p*

= .04). Variability in effect sizes across studies was observed (I^2 = 92.1%, τ^2 = .73) and

statistically significant (Q(10) = 125.84, *p* < .001) (Figure 2).

Figure 2: Forest plots of standardized mean differences (SMD) of odor identification and

cognitive performances in individuals with SCD vs. CN participants.

Each horizontal line represents the 95% confidence interval (CI) for an individual study, with the

square indicating the SMD estimate. The size of the square reflects the weight of the study in the

meta-analysis. The diamond at the bottom represents the overall pooled SMD and its 95% CI,

estimated using a random-effects model.

3.2.1. Moderator Analysis

Meta-regression analyses were performed to identify potential sources of heterogeneity.

Age differences between SCD and CN groups did not significantly moderate the observed

differences in odor identification performance (β = 0.09, SE = 0.20, 95% CI [-0.36, 0.54], *p*

= .67, R^2 = 0%), suggesting that age alone does not account for the variability in effect sizes

across studies (Figure 3). Neither *sex proportion (female %)* (β = -2.72, SE = 1.49, 95% CI [-

6.14, 0.70], *p* = .10, R^2 = 23.52%), *educational level* (years) (β = 0.03, SE = 0.39, 95% CI [-0.90,

0.95], *p* = .94, R^2 = 0%), or *test modality* ($F(4,6)$ = 1.56, *p* = .30) significantly moderated the

differences observed in odor identification between SCD and CN groups. However, cognitive

score on screening measures was a significant moderator (β = -1.79, SE = 0.64, 95% CI [-3.24, -

0.34], *p* = .02, R^2 = 46.47%), indicating that greater cognitive differences between groups were

associated with larger olfactory deficits (Figure 4).

Figure 3. Meta-regression and Test Modality Effects on Standardized Mean Difference (SMD) in

odor identification across SCD and CN groups.

The four panels depict meta-regression analyses evaluating the impact of age difference (top-

left), sex difference (top-right), and education difference (bottom-left). The bottom-right panel

shows the effect of test modality on SMD, with different olfactory identification tests (UPSIT,

SSIT, OPID, CC-SIT) represented as separate estimates with corresponding 95% confidence

intervals. Negative SMD values indicate poorer olfactory performance in SCD group compared

to CN group. Overall, none of these potential moderators reached statistical significance. Two

studies did not provide information regarding sex distribution,[54] and one did not report

educational level;[50,54] these studies were excluded from the respective moderator analyses.

Figure 4. Meta-regression Effect of Cognition on Standardized Mean Difference (SMD) in odor

identification across SCD and CN groups.

Negative SMD values suggest poorer olfactory performance in SCD compared to CN. The meta-

regression analysis identified cognitive scores on screening tests as a significant moderator (β = -

1.79, p = .02), indicating that greater cognitive differences between groups were associated with

larger deficits in odor identification.

3.2.2. Publication Bias

Publication bias was assessed using funnel plot inspection, Egger's test, and the trim-and-

fill method. Funnel plot symmetry indicated a low likelihood of substantial small-study effects or

selective reporting, which was further supported by a non-significant result from Egger's test (t =

-1.79, p = .11). The trim-and-fill analysis imputed two additional studies, resulting in an adjusted

pooled standardized mean difference of -0.30 (95% CI [-1.03, 0.44], p = .39), which was

substantially weaker and statistically non-significant compared tothe original estimate (SMD = -

0.67, 95% CI [-1.31, -0.03], p = .04). This adjustment suggests that the observed effect size

might have been overestimated in the presence of publication bias, and raises caution regarding

the robustness of the original effect (Figure 5).

Figure 5. Funnel Plots Assessing Publication Bias.

sFor each comparison (olfactory identification and cognition), the left panel displays the funnel

plot for publication bias, where each point represents an individual study's SMD plotted against

its standard error. The dotted lines indicate the expected distribution of studies in the absence of

bias. Symmetry suggests minimal small-study effects or selective reporting. The right panel

shows the trim-and-fill-adjusted funnel plot, with open circles representing imputed studies

added to correct for potential asymmetry. The adjusted pooled effect size was smaller than the

original estimate, suggesting possible overestimation due to publication bias. The wide

confidence interval of the adjusted estimate includes zero, indicating that the association may not

be significant after accounting for missing studies.

3.3. Main Effect (Cognitive Score on Screening Tests)

The meta-analysis of cognitive differences between SCD and CN also revealed a

significant effect (SMD = -0.31, 95% CI [-0.53, -0.08], $p =$ .01). Heterogeneity was moderate (I^2

= 39.3%, $\tau^2 = .05$, $p = .21$) but not statistically significant (Q(10) = 16.48, $p = 0.09$), indicating

that cognitive differences between SCD and CN are consistent across studies (Figure 2). As

heterogeneity remained below the critical threshold ($I^2 < 75\%$), no moderator analysis was

deemed necessary. Overall, the odor identification differences (SMD = -0.67) show a larger

effect size than cognitive differences (SMD = -0.31).

3.3.1. Publication Bias

Funnel plot inspection showed no strong evidence of asymmetry, and Egger's test was

again non-significant ($t = -1.88$ $p = .09$), indicating a low likelihood of publication bias (Figure

4). The trim-and-fill analysis imputed four additional studies, resulting in an adjusted pooled

SMD of -0.19 (95% CI [-0.42, 0.05], $p = .11$), which, although weaker and non-significant,

remained in the same direction.

4. Discussion

Here we report that individuals with SCD exhibited lower odor identification scores

compared to CN participants. Moderator analyses indicated that cognitive performance was

associated with olfactory scores, whereas age, sex, education, and test modality did not. These

findings confirm that individuals with SCD exhibit significantly reduced odor identification

performance compared to CN participants without cognitive complaints, extending the

hypothesis that olfactory deficits may serve as an early marker of the presence of AD pathology

and future cognitive decline during Stage 2 (Subjective Cognitive Decline). The effect size for

group differences in odor identification (SMD = -0.67) was larger than that observed for general

cognitive screening tests (SMD = -0.31), suggesting that olfactory impairment may be a more

sensitive measure of subtle neurodegenerative changes in individuals with SCD. Heterogeneity

was observed across studies in odor identification differences, which could not be explained by

age, sex proportion, education, or test modality. Cognitive performance across groups

significantly moderated olfactory scores, suggesting that olfactory performance may reflect

cognitive decline that remains within the normal range on standard neuropsychological

assessments in the preclinical SCD stage. Although publication bias did not appear to have

strongly influenced the results, the high level of heterogeneity highlights the need for further

investigation into additional contributing factors, including genetic predispositions and fluid

and/or imaging biomarkers of neurodegeneration, which may account for the variability in

olfactory identification deficits in SCD populations.

This meta-analysis confirmed that odor identification is reduced in SCD compared to CN

participants, confirming a trend observed in an initial meta-analysis published in 2021.[36] In the

context of the AD continuum, this finding suggests that odor identification is impaired prior to

the onset of cognitive deficits associated with MCI. This result aligns with studies demonstrating

associations between olfactory scores and AD tau or amyloid pathology biomarkers measured in

cognitively unimpaired,[28,57,58] and non-demented individuals.[59,60] A longitudinal study showed

that lower olfactory identification score correlates with baseline tau accumulation in primary

olfactory region and predicted accelerated progression of tau pathology in these regions ~2.5

years after.[28] Similarly, olfactory identification has been associated with hippocampal volume

and entorhinal cortex thickness in patients with MCI[20–26] and individuals with SCD without

cognitive impairment.[27] These findings suggest that odor identification tests could be among the

earliest objective measurements of AD-related damage to brain regions involved in olfactory

processing, occurring before the observable cognitive deficits.

Moderator analyses revealed that age, sex, education, and olfactory test modality did not

moderate the effect size. However, larger group differences on cognitive screening tests were

associated with larger differences in odor identification performance. Since all participants were

cognitively normal by definition, this result suggests that odor identification may serve as a

marker of subtle cognitive changes that remain undetected by standard cognitive screening tools.

This interpretation is consistent with a meta-analysis showing that odor identification scores are

associated with declarative memory in CN older adults.[61] Longitudinal studies have

demonstrated the predictive value of odor identification scores on future cognitive decline[29,62–65]

and conversion to MCI.[30,32,33] Taken together, these findings support the role of odor

identification as an early indicator of cognitive changes that may precede MCI in at-risk

individuals . For instance, lower olfactory identification scores in carriers of the ε4 allele of the

Apolipoprotein E (ApoE) gene have been associated with long-term episodic memory decline.[63]

It is important to note that reduced odor identification function is not specific to AD and

should not be used as a stand-alone diagnostic tool. Several other conditions can impair

olfaction, including neurological disorders such as Parkinson's disease,[66,67] and traumatic brain

injury,[68–70]; as well as non-neurological conditions like chronic rhinosinusitis,[71] among others.[72]

Therefore, interpretation of olfactory testing in the context of early AD detection must be

approached with caution. Two meta-analyses demonstrated that among olfactory functions,

olfactory identification is more specifically damaged in AD[13] and MCI[14] compared to a broader

loss of smell observed in conditions affecting the peripherical olfactory system[72] or in

Parkinson's disease.[13] Furthermore, a recent study showed that while a higher odor identification

score was associated with a higher probability of not having MCI (79%), lower score has limited

sensitivity (58%) in distinguishing MCI from SCD.[73] This suggests that the absence of an

olfactory identification deficit lowers the likelihood of AD, whereas a reduced score should lead

to further investigation. In such cases, more invasive and expensive diagnostic tools—such as,

blood-based or CSF biomarkers, structural MRI, PET scans, comprehensive neuropsychological

testing, and otorhinolaryngological examination—should be considered. Odor identification

might serve as a low-cost, non-invasive first-line screening tool for brain health, and low score

should trigger more in-depth evaluation to rule out other modifiable causes of olfactory

dysfunction that may benefit from early intervention addressing social isolation, auditive and

visual impairments, cardiovascular risk factors, depression, physical inactivity, among others.[74]

Our findings support the inclusion of an odor identification testing as an additional risk

factor in the SCD+ framework, which aims to refine the identification of individuals at elevated

risk of AD. This framework also includes criteria such as memory-specific complaints, onset of

SCD within the past five years, age over 60, external confirmation of cognitive decline, and

clinical help-seeking.[7] Given the associations between olfactory deficits and AD

biomarkers,[28,57,75] medial temporal atrophy,[18,20,23,24,26] and longitudinal cognitive

decline,[29,30,32,33,62–65] integrating odor identification into the SCD+ criteria could enhance the

stratification of risk for preclinical AD. Future studies should investigate whether combining

olfactory testing with the SCD+ framework improves the prediction of progression to MCI and

AD dementia.

The main limitation of this meta-analysis is that while meta-regression identified

cognitive performance as a significant moderator, other potential contributors to heterogeneity

such as genetic risk (e.g., APOE-ε4 status), neuropathological burden, or environmental factors

were not assessed due to limited available data. These potential variables could have enhanced

the comprehension of the significant heterogeneity observed in odor identification differences

between groups ($I^2 = 92.1\%$). Future research should incorporate these variables, particularly

amyloid and tau biomarkers, to strengthen the specificity of olfactory impairment as a preclinical

marker AD.[1]

5. Conclusion

The presence of odor identification impairments, observed alongside normal-range of

cognitive performance in individuals with SCD, reinforces the hypothesis that olfactory

impairment may constitute an early marker of AD preceding MCI. These findings align with

previous research associating odor identification impairment with AD biomarkers and

longitudinal cognitive decline. Future longitudinal research should explore whether combining

odor identification testingwith the SCD+ criteria improves the accuracy and precision of

predicting AD pathology, future cognitive decline, and progression to MCI or AD dementia.

6. Acknowledgements

Jobin is supported by scholarships from the Canadian Institutes of Health Research

(CIHR), the Fonds de Recherche Québec (FRQ) Santé, the Quebec Bio-Imaging Network, the

Université du Québec à Trois-Rivières, and MITACS. Zigrand is supported by the FRQ Santé.

Frasnelli is supported by CIHR (AFF_173514), FRQ Santé (352197), and the Natural Sciences

and Engineering Research Council of Canada (NSERC; RGPIN-2022-04813). Boller is

supported by the FRQ Société et culture (2023-NP-311368) and Réseau Québecois de recherche

sur le vieillissement. Albers received support from the NIH (R42 AG062130 and

U01DC019579).

7. Conflict of Interest

M.W.A. is a co-founder and shareholder of Aromha, Inc. He consults for Sudo Biosciences,

Merck, and Bristol Myers Squibb; has been sponsored for research presentations to Incyte; and

has received in-kind support from Eli Lilly and International Fragrances and Flavors.

8. References

1.   Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological
definition of Alzheimer's disease. *Alzheimer's & Dementia*. 2018;14(4):535-562.
doi:10.1016/j.jalz.2018.02.018

2.   Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of Cerebral Amyloid Pathology in
Persons Without Dementia: A Meta-analysis. *JAMA*. 2015;313(19):1924.
doi:10.1001/jama.2015.4668

3.   Jia J, Ning Y, Chen M, et al. Biomarker Changes during 20 Years Preceding Alzheimer's
Disease. *N Engl J Med*. 2024;390(8):712-722. doi:10.1056/NEJMoa2310168

4.   Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and
cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *The Lancet
Neurology*. 2013;12(4):11.

5.   Mintun MA, Lo AC, Evans CD, et al. Donanemab in Early Alzheimer's Disease. *n engl j
med*. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708

6.   van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. *n engl j
med*. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948

7.   Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on
subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimer's & Dementia*.
2014;10(6):844-852. doi:10.1016/j.jalz.2014.01.001

8.   Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive
decline. *The Lancet Neurology*. 2020;19(3):271-278. doi:10.1016/S1474-4422(19)30368-0

9.   Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in
subjective cognitive decline: The SCIENCe project. *Neurology*. 2020;95(1):e46-e58.
doi:10.1212/WNL.0000000000009724

10. Liew TM. Trajectories of subjective cognitive decline, and the risk of mild cognitive
impairment and dementia. *Alz Res Therapy*. 2020;12(1):135. doi:10.1186/s13195-020-
00699-y

11. Janssen O, Jansen WJ, Vos SJB, et al. Characteristics of subjective cognitive decline
associated with amyloid positivity. *Alzheimer's & Dementia*. 2021;18(10):1832-1845.
doi:10.1002/alz.12512

12. Pavisic IM, Lu K, Keuss SE, et al. Subjective cognitive complaints at age 70: associations
with amyloid and mental health. *J Neurol Neurosurg Psychiatry*. 2021;92(11):1215-1221.
doi:10.1136/jnnp-2020-325620

13. Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer's disease and Parkinson's disease
on olfaction: A meta-analysis. *Behavioural Brain Research*. 2012;231(1):60-74.
doi:10.1016/j.bbr.2012.02.047

14. Roalf DR, Moberg MJ, Turetsky BI, et al. A quantitative meta-analysis of olfactory
dysfunction in mild cognitive impairment. *J Neurol Neurosurg Psychiatry*. 2017;88(3):226-
232. doi:10.1136/jnnp-2016-314638

15. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions
and Alzheimer's disease. *Alzheimer's & Dementia*. 2015;11(1):70-98.
doi:10.1016/j.jalz.2014.04.514

16. Murphy C. Olfactory and other sensory impairments in Alzheimer disease. *Nat Rev Neurol*.
2019;15(1):11-24. doi:10.1038/s41582-018-0097-5

17. Jobin B, Boller B, Frasnelli J. Smaller grey matter volume in the central olfactory system in
mild cognitive impairment. *Experimental Gerontology*. 2023;183:112325.
doi:10.1016/j.exger.2023.112325

18. Chen B, Wang Q, Zhong X, et al. Structural and Functional Abnormalities of Olfactory-
Related Regions in Subjective Cognitive Decline, Mild Cognitive Impairment, and
Alzheimer's Disease. *International Journal of Neuropsychopharmacology*. 2021;25(5):361-
374. doi:10.1093/ijnp/pyab091

19. Vasavada MM, Wang J, Eslinger PJ, et al. Olfactory cortex degeneration in Alzheimer's
disease and mild cognitive impairment. *Journal of Alzheimer's disease*. 2015;45(3):947-958.
doi:10.3233/JAD-141947

20. Dhilla Albers A, Asafu-Adjei J, Delaney MK, et al. Episodic memory of odors stratifies
Alzheimer biomarkers in normal elderly: POEM: Odor Memory Biomarker in Normal
Elderly. *Ann Neurol*. 2016;80(6):846-857. doi:10.1002/ana.24792

21. Kose Y, Hatamoto Y, Takae R, et al. Association between the inability to identify particular
odors and physical performance, cognitive function, and/or brain atrophy in community-
dwelling older adults from the Fukuoka Island City study. *BMC Geriatr*. 2021;21(1):421.
doi:10.1186/s12877-021-02363-y

22. Hagemeier J, Woodward MR, Rafique UA, et al. Odor identification deficit in mild cognitive
impairment and Alzheimer's disease is associated with hippocampal and deep gray matter
atrophy. *Psychiatry Research: Neuroimaging*. 2016;255:87-93.
doi:10.1016/j.pscychresns.2016.08.003

23. Kjelvik G, Saltvedt I, White LR, et al. The brain structural and cognitive basis of odor
identification deficits in mild cognitive impairment and Alzheimer's disease. *BMC Neurol*.
2014;14(1):168. doi:10.1186/s12883-014-0168-1

24. Murphy C, Jernigan TL, Fennema-Notestine C. Left hippocampal volume loss in
Alzheimer's disease is reflected in performance on odor identification: A structural MRI
study. *J Int Neuropsychol Soc*. 2003;9(3):459-471. doi:10.1017/S1355617703930116

25. Yoshii F, Onaka H, Kohara S, Ryo M, Takahashi W. Association of Smell Identification
Deficit with Alzheimer's Disease Assessment Scale-Cognitive Subscale, Japanese Version
Scores and Brain Atrophy in Patients with Dementia. *Eur Neurol*. 2019;81(3-4):145-151.
doi:10.1159/000501311

26. Yu H li, Chen Z juan, Zhao J wei, Duan S rong, Zhao J kun. Olfactory Impairment and
Hippocampal Volume in a Chinese MCI Clinical Sample. *Alzheimer Disease & Associated*
Disorders. 2019;33(2):124-128. doi:10.1097/WAD.0000000000000305

27. Papadatos Z, Phillips NA. Olfactory function reflects episodic memory performance and
atrophy in the medial temporal lobe in individuals at risk for Alzheimer's disease.
Neurobiology of Aging. 2023;128:33-42. doi:10.1016/j.neurobiolaging.2023.04.001

28. Diez I, Ortiz-Terán L, Ng TSC, et al. Tau propagation in the brain olfactory circuits is
associated with smell perception changes in aging. *Nat Commun*. 2024;15(1):4809.
doi:10.1038/s41467-024-48462-3

29. Devanand DP, Lee S, Manly J, et al. Olfactory deficits predict cognitive decline and
Alzheimer dementia in an urban community. *Neurology*. 2015;84(2):182-189.
doi:10.1212/WNL.0000000000001132

30. Roberts RO, Christianson TJ, Kremers WK, et al. Association between olfactory dysfunction
and amnestic mild cognitive impairment and Alzheimer disease dementia. *JAMA neurology*.
2016;73(1):93-101.

31. Swan GE, Carmelli D. Impaired Olfaction Predicts Cognitive Decline in Nondemented Older
Adults. *Neuroepidemiology*. 2002;21(2):58-67. doi:10.1159/000048618

32. Wheeler PL, Murphy C. Olfactory Measures as Predictors of Conversion to Mild Cognitive
Impairment and Alzheimer's Disease. *Brain Sciences*. 2021;11(11):1391.
doi:10.3390/brainsci11111391

33. Wilson RS, Schneider JA, Arnold SE, Tang Y, Boyle PA, Bennett DA. Olfactory
Identification and Incidence of Mild Cognitive Impairment in Older Age. *Arch Gen*
Psychiatry. 2007;64(7):802. doi:10.1001/archpsyc.64.7.802

34. Devanand DP, Liu X, Cohen H, et al. Long-Term Test–Retest Reliability of the UPSIT in
Cognitively Intact Older Adults. *Chemical senses*. 2019;44(6):365-369.

35. Conti MZ, Vicini-Chilovi B, Riva M, et al. Odor Identification Deficit Predicts Clinical
Conversion from Mild Cognitive Impairment to Dementia Due to Alzheimer's Disease.
Archives of Clinical Neuropsychology. 2013;28(5):391-399. doi:10.1093/arclin/act032

36. Jobin B, Zahal R, Bussières EL, Frasnelli J, Boller B. Olfactory Identification in Subjective
Cognitive Decline: A Meta-Analysis. Pike K, ed. *JAD*. 2021;79(4):1497-1507.
doi:10.3233/JAD-201022

37. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA:
A Brief Screening Tool For Mild Cognitive Impairment: MOCA: A BRIEF SCREENING
TOOL FOR MCI. *Journal of the American Geriatrics Society*. 2005;53(4):695-699.
doi:10.1111/j.1532-5415.2005.53221.x

38. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." *Journal of Psychiatric
Research*. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6

39. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin'sticks': olfactory performance
assessed by the combined testing of odor identification, odor discrimination and olfactory
threshold. *Chemical senses*. 1997;22(1):39-52.

40. Jobin B, Magdamo C, Delphus D, et al. The AROMHA brain health test is a remote olfactory
assessment to screen for cognitive impairment. *Scientific Reports*. 2025;15(9290).

41. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell
Identification Test: a rapid quantitative olfactory function test for the clinic. *The
Laryngoscope*. 1984;94(2):176-178.

42. Doty RL, Marcus A, William Lee W. Development of the 12-Item Cross-Cultural Smell
Identification Test(CC-SIT). *Laryngoscope*. 1996;106(3):353-356. doi:10.1097/00005537-
199603000-00021

43. Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for
preclinical and clinical studies, systematic review and meta-analysis, and clinical practice
guideline: a systematic review: Methodological quality assessment tools. *Journal of
Evidence-Based Medicine*. 2015;8(1):2-10. doi:10.1111/jebm.12141

44. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing
the quality of nonrandomised studies in meta-analyses. *Ottawa: Ottawa Hospital Research
Institute*. Published online 2011.

45. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with
binary outcome. *Statistics in medicine*. 2001;20(24):3875-3889.

46. IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction
intervals in meta-analysis. *BMJ Open*. 2016;6(7):e010247. doi:10.1136/bmjopen-2015-
010247

47. Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study
variance and its uncertainty in meta-analysis. *Research Synthesis Methods*. 2016;7(1):55-79.
doi:10.1002/jrsm.1164

48. Tahmasebi R, Zehetmayer S, Stögmann E, Lehrner J. Awareness of Olfactory Dysfunction in
Subjective Cognitive Decline, Mild Cognitive Decline, and Alzheimer's Disease. *Chem*
Percept. Published online June 24, 2019. doi:10.1007/s12078-019-09267-7

49. Tahmasebi R, Zehetmayer S, Pusswald G, Kovacs G, Stögmann E, Lehrner J. Identification
of odors, faces, cities and naming of objects in patients with subjective cognitive decline,
mild cognitive impairment and Alzheimer´s disease: a longitudinal study. *International*
psychogeriatrics. 2019;31(4):537-549.

50. Bouhaben J, Delgado-Lima AH, Delgado-Losada ML. Olfactory Identification as a
Biomarker for Cognitive Impairment: Insights from Healthy Aging, Subjective Cognitive
Decline, and Mild Cognitive Impairment. *EJIHPE*. 2024;14(12):2978-3000.
doi:10.3390/ejihpe14120196

51. Jobin B, Magdamo C, Delphus D, et al. AROMHA Brain Health Test: A Remote Olfactory
Assessment as a Screen for Cognitive Impairment. Published online August 6,
2024:2024.08.03.24311283. doi:10.1101/2024.08.03.24311283

52. Risacher SL, Tallman EF, West JD, et al. Olfactory identification in subjective cognitive
decline and mild cognitive impairment: Association with tau but not amyloid positron
emission tomography. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease*
Monitoring. 2017;9:57-66.

53. Schmicker M, Frühling I, Menze I, et al. The Potential Role of Gustatory Function as an
Early Diagnostic Marker for the Risk of Alzheimer's Disease in Subjective Cognitive
Decline. *Journal of Alzheimer's Disease Reports*. 2023;7(1):249-262.
doi:10.3233/ADR220092

54. Sohrabi HR, Bates KA, Rodrigues M, et al. Olfactory dysfunction is associated with
subjective memory complaints in community-dwelling elderly individuals. *Journal of*
Alzheimer's Disease. 2009;17(1):135-142.

55. Wang Q, Chen B, Zhong X, et al. Olfactory Dysfunction Is Already Present with Subjective
Cognitive Decline and Deepens with Disease Severity in the Alzheimer's Disease Spectrum.
JAD. 2021;79(2):585-595. doi:10.3233/JAD-201168

56. Weber MT. *Odor Memory in Older Adults with and without Cognitive Impairments*. Ph.D.
State University of New York at Albany; 2003.
https://search.proquest.com/docview/304658367?accountid=12543

57. Lafaille-Magnan ME, Poirier J, Etienne P, et al. Odor identification as a biomarker of
preclinical AD in older adults at risk. *Neurology*. 2017;89(4):327-335.
doi:10.1212/WNL.0000000000004159

58. Tian Q, Bilgel M, Moghekar AR, Ferrucci L, Resnick SM. Olfaction, Cognitive Impairment,
and PET Biomarkers in Community-Dwelling Older Adults. *JAD*. 2022;86(3):1275-1285.
doi:10.3233/JAD-210636

59. Dong Y, Li Y, Liu K, et al. Anosmia, mild cognitive impairment, and biomarkers of brain
aging in older adults. *Alzheimer's & Dementia*. 2023;19(2):589-601. doi:10.1002/alz.12777

60. Ramirez-Gomez L, Albers MW, Baena A, et al. Olfactory Function and Markers of Brain
Pathology in Non-Demented Individuals with Autosomal Dominant Alzheimer's Disease.
JAD. 2022;88(2):721-729. doi:10.3233/JAD-220075

61. Jobin B, Roy-Côté F, Frasnelli J, Boller B. Olfaction and Declarative Memory in Aging: A
Meta-analysis. *Chemical Senses*. 2023;48:bjad045. doi:10.1093/chemse/bjad045

62. Dintica CS, Marseglia A, Rizzuto D, et al. Impaired olfaction is associated with cognitive
decline and neurodegeneration in the brain. *Neurology*. 2019;92(7):e700-e709.
doi:10.1212/WNL.0000000000006919

63. Olofsson JK, Larsson M, Roa C, Wilson DA, Jonsson Laukka E. Interaction Between Odor
Identification Deficit and APOE4 Predicts 6-Year Cognitive Decline in Elderly Individuals.
Behav Genet. 2020;50(1):3-13. doi:10.1007/s10519-019-09980-9

64. Sohrabi HR, Bates KA, Weinborn MG, et al. Olfactory discrimination predicts cognitive
decline among community-dwelling older adults. *Transl Psychiatry*. 2012;2(5):e118-e118.
doi:10.1038/tp.2012.43

65. Windon MJ, Kim SJ, Oh ES, Lin SY. Predictive value of olfactory impairment for cognitive
decline among cognitively normal adults. *The Laryngoscope*. 2019;130(4):840-847.
doi:10.1002/lary.28166

66. Doty RL. Olfactory dysfunction in Parkinson disease. *Nature Reviews Neurology*.
2012;8(6):329-339. doi:10.1038/nrneurol.2012.80

67. Fullard ME, Morley JF, Duda JE. Olfactory Dysfunction as an Early Biomarker in
Parkinson's Disease. *Neurosci Bull*. 2017;33(5):515-525. doi:10.1007/s12264-017-0170-x

68. Lecuyer Giguère F, Frasnelli A, De Guise É, Frasnelli J. Olfactory, cognitive and affective
dysfunction assessed 24 hours and one year after a mild Traumatic Brain Injury (mTBI).
Brain Injury. 2019;33(9):1184-1193. doi:10.1080/02699052.2019.1631486

69. Zigrand C, Jobin B, Lecuyer Giguère F, Giguère JF, Boller B, Frasnelli J. Olfactory
perception in patients with a mild traumatic brain injury: a longitudinal study. *Brain Injury*.
2022;36(8):985-990. doi:10.1080/02699052.2022.2109734

70. Proskynitopoulos P, Stippler M, Kasper E. Post-traumatic anosmia in patients with mild
traumatic brain injury (mTBI): A systematic and illustrated review. *Surg Neurol Int*.
2016;7(11):263. doi:10.4103/2152-7806.181981

71. Rombaux P, Huart C, Levie P, Cingi C, Hummel T. Olfaction in chronic rhinosinusitis.
Current allergy and asthma reports. 2016;16:1-12.

72. Patel ZM, Holbrook EH, Turner JH, et al. International consensus statement on allergy and
rhinology: Olfaction. *Int Forum Allergy Rhinol*. 2022;12(4):327-680. doi:10.1002/alr.22929

73. Jobin B, Philips N, Frasnelli J, Boller B, CIMA-Q. Associations between declarative memory
and olfactory identification in older adults at risk for alzheimer's disease: preliminary results
from the cima-q cohort. In: International Conference on Alzheimer's and Parkinson's
Diseases and Related Neurological Disorders (ADPD) 2025; 2025.

74. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024
report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.

75. Klein J, Yan X, Johnson A, et al. Olfactory Impairment Is Related to Tau Pathology and
Neuroinflammation in Alzheimer's Disease. Gordon B, ed. *JAD*. 2021;80(3):1051-1065.
doi:10.3233/JAD-201149